Site-Specific Antibacterial Strategy for Multi-Pathway Treatment of Drug-Resistant Skin Infections.

Summary

A dissolvable microneedle patch co-delivering vancomycin and photoactive black phosphorus quantum dots enabled localized, sustained, and synergistic antibacterial therapy. In vivo MRSA models showed faster wound closure, smaller abscesses, reduced inflammation, and enhanced tissue regeneration under light activation.

Key Findings

• A dissolvable microneedle array penetrated the skin barrier to co-deliver vancomycin and BPQDs encapsulated in macrophage membrane-coated cationic liposomes.
• Light-activated BPQDs generated localized hyperthermia and ROS, synergizing with vancomycin to eradicate bacteria and mitigate resistance development.
• In vivo, the platform accelerated wound closure, reduced abscess size, suppressed inflammation, and promoted tissue regeneration in MRSA-infected models.

Clinical Implications

If translated, this approach could offer dermatology and wound-care teams a targeted adjunct to standard antibiotics for MRSA abscesses and infected wounds, potentially shortening healing time and lowering recurrence.

Limitations

• Preclinical animal data only; no human safety or efficacy data.
• Requires external light activation and may involve thermal exposure; long-term tissue safety and manufacturing scalability need evaluation.

Future Directions

First-in-human feasibility and dose-finding studies, optimization of light parameters, and head-to-head comparisons with standard wound-care protocols in MRSA infections.